Table 1.
Nurse’s preference with self-assembly formulation [32]
| Attribute | Mean relative importance score (scale of 1–10) | Mean preference score (scale of 1–10) | |
|---|---|---|---|
| Octreotide LAR | Lanreotide depot | ||
| Confidence that a full dose has been delivered | 9.5 | 6.8 | 9.5 |
| High product efficacy | 9.4 | 7.5 | 8.6 |
| Good safety | 9.4 | 5.8 | 8.9 |
| Low risk of clogging | 8.8 | 3.7 | 9.4 |
| Easy/convenient preparation and injection | 8.8 | 3.8 | 9.4 |
| Easy to teach | 8.3 | 4.4 | 9.1 |
| Low risk of needlestick injuries | 8.2 | 4.9 | 8.8 |
| Prefilled device | 8.1 | 3.1 | 9.5 |
| Calm environment for patient | 7.9 | 6.4 | 7.9 |
| Fast administration (preparation & injection) | 7.9 | 3.7 | 9.3 |
| Sturdy plunger | 7.9 | 7.7 | 7.5 |
| Transparent device | 7.8 | 7.8 | 9.2 |
| Comfortable device to hold | 7.7 | 6.3 | 7.6 |
| Short/thin needle | 7.6 | 3.8 | 7.1 |
| Depth of injection (IM vs deep SC) | 7.2 | 5.6 | 8.1 |
| Self-injection possible | 6.8 | 3.2 | 8.4 |
| Overall preference score | 70 | 114 | |
Nurses rated a predefined list of attributes on a scale of 1 to 10 (1 = not important/not preferred, 10 = most important/most preferred). Lanreotide depot (new device) received higher preference scores in all attributes except for the sturdiness of the plunger. Overall preference score, which included scores in all 16 attributes weighted by relative importance, was significantly higher with lanreotide depot (P < 0.01)
IM intramuscular, SC subcutaneous